AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 11 min read$AVTX

Doyle Mittie sold $14K of AVTX

Doyle Mittie (Chief Medical Officer) sold 679 shares of Avalo Therapeutics, Inc. (AVTX) at $20.00 on 2026-08-28 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Doyle Mittie
Published Sep 1, 2026, 8:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 1, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$AVTX
Neutral
high confidence
Mentioned
$AVTX
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$AVTXNeutralLow
01

Why it matters

The sale is routine and unlikely to affect AVTX's valuation.

02

Market read

Limited relevance; typical insider transaction.

03

What to watch

Potential upcoming clinical data may outweigh the impact of this sale.

Relevance 2/10Novelty 4/10Timing: today

Background

Form 4 filing discloses insider transactions required by SEC.

Company-level read

Ticker impact

$AVTXNeutralHigh confidence
Context

Chief Medical Officer sold 679 shares for $13,580 via a 10b5-1 plan on 2026-08-28.

Expected impact

No significant movement expected.

Evidence & confidence

The transaction size is small relative to total holdings and market cap.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Insider sale could signal confidence in future upside despite small size.

Key entities

  • Officer
    Doyle Mittie

    Chief Medical Officer of Avalo Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

AVTX insider trading history →

Related articles

SEP 10
$AVTXMedAI 8/10

AVTX: Advancing anti-IL-1 beta therapy to phase III for HS, expanding indications, and securing strong financial support

Avalo Therapeutics (AVTX) is advancing its anti-IL-1 beta antibody, abdakibart, to phase III trials for hidradenitis suppurativa (HS) after positive phase II results. The company plans to expand indications in dermatology and rheumatology, develop a long-acting version, and secure financial support. The strategy includes differentiated dosing and device approaches.

tradingview.com1 min
AUG 6
$AVTXMedAI 8/10

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

Avalo Therapeutics (Nasdaq: AVTX) reported Q2 2026 results and business updates. The company plans to start a registrational Phase 3 for abdakibart in hidradenitis suppurativa in H1 2027 and expects to submit an IND for AVTX-010 in H1 2027. Cash, cash equivalents and investments were $472.2M at June 30, 2026, funding operations into 2029. Q2 net loss was $36.4M.

finanznachrichten.de6 min
AUG 6
$AVTXMed

Avalo Therapeutics, Inc. (AVTX): Results of Operations and Financial Condition

Avalo Therapeutics, Inc. (AVTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates • Plans to initiate a registrational Phase 3 program evaluating abdakibart in hidradenitis suppurativa (HS) in the first half of 2027 • Expanded pipeline with AVTX-010, a lon

SEC EDGAR 8-K6 min